Organization
Ionis Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Ionis Pharmaceuticals, Inc.
... Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that its New Drug Application (NDA) for inotersen ...
... 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious ...
... from one early (Phase 1/2a) clinical trial of an antisense oligonucleotide called IONIS-HTT Rx , made by California biotech Ionis Pharmaceuticals, suggest that this approach ...
... from one early (Phase 1/2a) clinical trial of an antisense oligonucleotide called IONIS-HTT Rx , made by California biotech Ionis Pharmaceuticals, suggest that this approach ...
... CARLSBAD - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has earned a $ 5 ...
... research to the investment community. Today we are offering reports on AMRN, IONS, ENDP, and TEVA which can be accessed for free by signing up ...
... Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has earned a $5 million milestone ...
... Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration ...
... Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that its license agreement with Roche to develop ...
... said. UMass licensed their discovery to a Carlsbad, Calif., biotech firm called Isis Pharmaceuticals. The deal gives UMass and Singh a total of 2 percent ...
... Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will ...
... 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious ...
... seven years ago but saw no tumor response. That drug came from Ionis Pharmaceuticals, which later embarked on its own eIF4FE-targeting antisense trial. Ionis’ program ...
... we knew that that could be a cure." The research, supported by Ionis Pharmaceuticals in Carlsbad, Calif., was conducted by scientists at more than half ...
... had a wonderful weekend. This is Sy. An experimental injectable drug from Ionis Pharmaceuticals is one of the first to show potential in treating the ...
... the problematic huntingtin protein from every being made. The treatment is called Ionis-HTTRx and made by Ionis Pharmaceuticals, the Guardian reports, Seventy-five percent of the ...
... An experimental injectable drug from Ionis Pharmaceuticals is one of the first to show potential in treating the ...
... Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Roche has exercised its option to license ...
... the huntingtin protein damage nerve cells in the brain. The new drug, Ionis-HTTRx, was shown to be safe in humans and lowered levels of mutant ...
... CARLSBAD, Calif. - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will ...
... Miels, GSK's new head of pharma, told Reuters. ( Reuters ) 3. Ionis Pharmaceuticals' experimental Huntington's disease drug IONIS-HTT(Rx) tackled a protein defect for the ...
... Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will ...
... CARLSBAD, Calif. - Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed a second orally delivered ...
Want to see the full history on Ionis Pharmaceuticals, Inc.? Upgrade to RelSci Pro now!
Start My Free Trial